Development of (r, s')-MNF as a dual-targeted therapy for pancreatic cancer
Ended Project Grant Awarded Last action
- Award ID
- R41CA275625
- Recipient
-
PAZ Pharmaceuticals LLC UEI E5RFQLHT2FV5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $770,114
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Washington, DC, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pancreatic ductal adenocarcinoma (pdac) is the third leading cause of cancer death in the U.S. With a 5-year survival rate of
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$164 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $385,139 | |
| Original award | $385,139 |
Quick answers
Who received award R41CA275625?
R41CA275625 was awarded to PAZ Pharmaceuticals LLC by National Cancer Institute (National Institutes of Health) on September 1, 2022.
How much is award R41CA275625 worth?
$770,114 has been obligated on R41CA275625.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award